Mayo Clinic Multiple Myeloma SPORE
The Mayo Clinic Multiple Myeloma SPORE is a dynamic, productive, translational cancer research initiative that aims to support innovative, interactive, rigorous translational research on multiple myeloma. The SPORE leverages exceptional laboratory, translational and clinical expertise to study treatment resistance, gene-environment interactions and early detection in order to improve care and outcomes.
The unifying theme of the Multiple Myeloma SPORE is to conduct research exploring the translational implications of host factors and tumor biology and their relationship with the tumor microenvironment.
Our investigators are applying the steadily improving genetic characterization of multiple myeloma to enable early detection. We're developing a new genetic definition of the earliest form of malignant multiple myeloma that requires treatment, in contrast to a benign condition that does not require treatment.
At the opposite end of the spectrum, we're characterizing the genetic features that contribute to ultra-high-risk multiple myeloma, for which current therapies are not effective.
This work is complemented by efforts aimed at identifying the underlying mechanisms of resistance to T cell-directed therapies.
Specific aims
The SPORE has several specific aims.
Supporting translational research
We support translational research on multiple myeloma based on sound scientific rationale through our three major research projects. These are new projects exploring concepts that emerged from research during the SPORE's previous funding period. The projects address key areas of unmet need for multiple myeloma research, with plans to translate the findings to patient care through new clinical trials.
Enhancing research infrastructure
Vital support from three cores within the SPORE enhances the infrastructure behind our translational research: Administrative Core, Biospecimens and Clinical Database Core, and Biostatistics and Bioinformatics Core.
Supporting novel concepts and rising investigators
The Developmental Research Program and the Career Enhancement Program are two funding opportunities within the SPORE that support novel translational research concepts based on peer review and encourage junior faculty toward a career in translational research.
NCI funding
The U.S. National Cancer Institute (NCI) has funded the Mayo Clinic Multiple Myeloma SPORE since 2015. The SPORE received a five-year, $11.5 million grant renewal from the NCI in September 2021.
Principal investigator
The principal investigator for the Multiple Myeloma SPORE is Leif Bergsagel, M.D. Dr. Bergsagel is an oncologist at Mayo Clinic's campus in Scottsdale, Arizona, and a professor of medicine at Mayo Clinic College of Medicine and Science. He has the distinction of being the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research II.
Contact
Leif Bergsagel, M.D.
Principal Investigator
Mayo Clinic Multiple Myeloma SPORE
Mayo Clinic
Collaborative Research Building
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
Email: bergsagel.leif@mayo.edu
